Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

Academic Article
Publication Date:
2024
Short description:
Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL / Koenig, F., Spiertz, C., Millar, D., Rodríguez-Navarro, S., Machín, N., Van Dessel, A., Genescà, J., Pericàs, J.M., Posch, M., Sánchez-Montalva, A., Estevez, A.B., Sánchez, À., Sanjuan, A., Sena, E., Granados, E., Arévalo De Andrés, E., Nuñez, F., Arteaga, G., Fuentes Ruiz, G.P., Fernández, G., et al.. - In: ECLINICALMEDICINE. - ISSN 2589-5370. - 67:(2024). [10.1016/j.eclinm.2023.102384]
abstract:
Unlabelled: Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients. Funding: Innovative Medicines Initiative 2 Joint Undertaking with support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
Iris type:
1.1.1 Articolo in rivista - Review
List of contributors:
Authors of the University:
Handle:
https://iris.unisr.it/handle/20.500.11768/156156
Full Text:
Published in:
ECLINICALMEDICINE
Journal